<p>Actinium Pharmaceuticals，这家医疗行业公司，昨天被华尔街分析师重新评估。Maxim Group 的分析师 Jason McCarthy 维持了对该股票的买入评级，并设定了 5.00 美元的目标价。</p>
<h3>在 TipRanks Premium 上享受 50% 的折扣，信心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Jason McCarthy 给予买入评级是基于与 Actinium Pharmaceuticals 的有前景的发展相关的多种因素。Actinium 的 ATNM-400 是一种利用铀-225 的靶向放射治疗，已在多种癌症类型中显示出显著的抗肿瘤活性，包括乳腺癌、肺癌和前列腺癌。这包括在耐药模型中的有效性，使 Actinium 在放射药物和抗体药物结合物领域中处于领先地位。</p>
<p>此外，该公司资本充足，财务状况良好，截至 2025 年第三季度末拥有 5340 万美元的现金，为持续发展提供了坚实的基础。ATNM-400 的未披露靶点与肿瘤进展和耐药性相关，为未来的增长增添了一层神秘和潜力。这些因素共同支撑了 McCarthy 对 Actinium Pharmaceuticals 的乐观展望和买入评级。</p>
<p>McCarthy 覆盖医疗行业，关注的股票包括 Actinium Pharmaceuticals、Plus Therapeutics 和 SCYNEXIS。根据 TipRanks 的数据，McCarthy 的平均回报率为-7.8%，推荐股票的成功率为 37.42%。</p>
<p>在昨天发布的另一份报告中，H.C. Wainwright 也重申了对该股票的买入评级，目标价为 4.00 美元。</p>

Actinium制药

<p>Actinium 制药获得了 Maxim Group 分析师 Jason McCarthy 的买入评级，目标价为 5.00 美元，原因是其 ATNM-400 放射治疗的有希望进展以及强劲的财务状况。该公司拥有 5340 万美元的现金，支持未来的增长。H.C. Wainwright 也重申了买入评级，目标价为 4.00 美元</p>

<p>Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.</p>
<div class="lb-trans"><p>Actinium Pharmaceuticals，这家医疗行业公司，昨天被华尔街分析师重新评估。Maxim Group 的分析师 Jason McCarthy 维持了对该股票的买入评级，并设定了 5.00 美元的目标价。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 的折扣，信心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ promising developments. Actinium’s ATNM-400, a targeted radiotherapy utilizing Actinium-225, has shown significant anti-tumor activity across various cancer types, including breast, lung, and prostate cancers. This includes effectiveness in treatment-resistant models, which positions Actinium as a leader in the radiopharmaceutical and antibody-drug conjugate sectors.</p>
<div class="lb-trans"><p>Jason McCarthy 给予买入评级是基于与 Actinium Pharmaceuticals 的有前景的发展相关的多种因素。Actinium 的 ATNM-400 是一种利用铀-225 的靶向放射治疗，已在多种癌症类型中显示出显著的抗肿瘤活性，包括乳腺癌、肺癌和前列腺癌。这包括在耐药模型中的有效性，使 Actinium 在放射药物和抗体药物结合物领域中处于领先地位。</p>
</div><p>Furthermore, the company is well-capitalized with a strong financial position, having $53.4 million in cash at the end of the third quarter of 2025, providing a solid runway for continued development. The undisclosed target of ATNM-400, which is associated with tumor progression and resistance, adds a layer of intrigue and potential for future growth. These factors collectively underpin McCarthy’s optimistic outlook and Buy rating for Actinium Pharmaceuticals.</p>
<div class="lb-trans"><p>此外，该公司资本充足，财务状况良好，截至 2025 年第三季度末拥有 5340 万美元的现金，为持续发展提供了坚实的基础。ATNM-400 的未披露靶点与肿瘤进展和耐药性相关，为未来的增长增添了一层神秘和潜力。这些因素共同支撑了 McCarthy 对 Actinium Pharmaceuticals 的乐观展望和买入评级。</p>
</div><p>McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Plus Therapeutics, and SCYNEXIS. According to TipRanks, McCarthy has an average return of -7.8% and a 37.42% success rate on recommended stocks.</p>
<div class="lb-trans"><p>McCarthy 覆盖医疗行业，关注的股票包括 Actinium Pharmaceuticals、Plus Therapeutics 和 SCYNEXIS。根据 TipRanks 的数据，McCarthy 的平均回报率为-7.8%，推荐股票的成功率为 37.42%。</p>
</div><p>In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.</p>
<div class="lb-trans"><p>在昨天发布的另一份报告中，H.C. Wainwright 也重申了对该股票的买入评级，目标价为 4.00 美元。</p>
</div>

Actinium 制药：有前景的发展和稳健的财务状况推动买入评级